John Harris, a professor of medical ethics at Manchester University, said companies such as Novartis should not be allowed to block attempts at using more cost-effective treatments to maximise their profits.
"It is legitimate for healthcare providers to appraise and approve off-label treatments which are significantly more cost-effective than those that pharma are prepared to licence," Professor Harris said.
No comments:
Post a Comment